Additionally, the PD-L1+ CTECs count originating from tumor cells exhibited minimal variation across treatment phases from T0 to T6, whereas CTC PD-L1 levels decreased significantly during therapy in P11 (Figures 6A and 6B). The gene discussed is CD274; the disease is neoplasm.